Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: The ENCORE I study (evaluation of nifedipine and cerivastatin on recovery of coronary endothelial function)

Circulation

Volumn 107, Issue 3, 2003, Pages 422-428

  Luscher, Thomas F ^a   Azancot, I ^b   Balbi, M ^b   Bonnier, J J R M ^b   Desmet, W ^b   Diederich, K W ^b   Drexel, H ^b   Dubois Rande, J ^b   Erbel, R ^b   Da Gama Ribeiro, V ^b   Glogar, H ^b   Hanrath, P ^b   Hess, O M ^b   Heyer, G ^b   Hugenholtz, P G ^b   Lafont, A ^b   Meinertz, T ^b   Munzel T ^b   Rafflenbeul, W ^b   Meredith, I T ^b   Pieper, M ^b   Quitzau, K ^b   Rutsch, W ^b   Seabra Gomes, R ^b   Sutsch G ^b   Suttorp, M J ^b   Te Riele, J A M ^b   Van Boven, A J ^b   Van den Branden, F ^b   Verna, E ^b   Vrolix, M ^b   Weidinger, F ^b   Werner, G S ^b   Zeiher, A M ^b   more..

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE

Author keywords

Acetylcholine; Angiography; Coronary disease; Drugs; Endothelium

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; ADENOSINE; AMLODIPINE BESYLATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCERYL TRINITRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIFEDIPINE; NITRATE; PLACEBO; SIMVASTATIN; STATINE DERIVATIVE; TICLOPIDINE; VASODILATOR AGENT;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY CONSTRICTION; ARTERY DIAMETER; ARTICLE; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FATALITY; ENDOTHELIUM CELL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; VASOSPASM;

ACETYLCHOLINE; ADULT; CALCIUM CHANNEL BLOCKERS; CHOLESTEROL; CORONARY ARTERIOSCLEROSIS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIUM; NIFEDIPINE; PYRIDINES; VASOCONSTRICTION;

EID: 0037469203     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000046488.52939.BF     Document Type: Article

References (41)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
2. Lüscher TF, Vanhoutte PM. The Endothelium: Modulator of Cardiovascular Function. Boca Raton, Fla: CRC Press; 1990:1-250.
3. Lüscher TF, Noll G. The endothelium in coronary vascular control. In: Braunwald E, ed. Heart Disease, Update 3. Philadelphia, Pa: Saunders; 1995:1-10.
4. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986;315:1046-1051.
5. Schachinger V. Zeiher AM. Quantitative assessment of coronary vasoreactivity in humans in vivo: importance of baseline vasomotor tone in atherosclerosis. Circulation. 1995;92:2087-2094.
6. Tanner FC, Noll G, Boulanger CM, et al. Oxidized low density lipoproteins inhibit relaxation of porcine coronary arteries: role of scavenger receptor and endothelium-derived nitric oxide. Circulation. 1991;83:2012-2020.
7. Lüscher TF, Raij L, Vanhoutte PM. Endothelium-dependent vascular responses in normotensive and hypertensive Dah1 rats. Hypertension. 1987;9:157-163.
8. Linder L, Kiowski W, Bühler FR, et al. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo: blunted response in essential hypertension. Circulation. 1990;81:1762-1767.
9. Panza JA, Quyyumi AA, Brush JE, et al. Abnormal endotheliumdependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22-27.
10. Cosentino F, Hishikawa K, Katusic ZS, et al. High glucose increases nitric oxide synthase expression and superoxideanion generation in human aortic endothelial cells. Circulation. 1997;96:25-28.
11. Johnstone MT, Creager SJ, Scales KM, et al. Impaired endotheliumdependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 1993;88:2510-2516.
12. Mugge A, Elwell JH, Peterson TE, et al. Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits. Circ Res. 1991;69:1293-1300.
13. Yang Z, Kozai T, van der Loo B, et al. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J Am Coll Cardiol. 2000;36:1691-1697.
14. Tschudi MR, Criscione L, Novosel D, et al. Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation. 1994;89:2212-2218.
15. Taddei S, Virdis A, Ghiadoni L, et al. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension. 2001;37:943-948.
16. Lüscher TF, Zeiher AM, Meinertz T, et al. Effects of calcium antagonism and HMG-CoA-enzyme reductase inhibition on endothelial function and atherosclerosis: rationale and outline of the ENCORE trials. J Cardiovasc Pharmacol. 1997;30:S48-S52.
17. Spiller P, Schmiel FK, Politz B, et al. Measurement of systolic and diastolic flow rates in the coronary artery system by x-ray densitometry. Circulation. 1983;68:337-347.
18. Reiber JHC, Schiemanck LR, van der Zwet PMJ, et al. State of the art in quantitative coronary angiography as of 1996. In: JHC Reiber, EE van der Wall, eds. Cardiovascular Imaging. Dordrecht. Netherlands; Kluwer Academic Publishers; 1996:39-56.
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
20. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinalapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 1196;94:258-265.
21. Davignon J, Hanefeld M, Nakaya N, et al. Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies. Am J Cardiol. 1998;82(4B):32J-39J.
22. Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 2001;103:2885-2890.
23. The US Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. 2001 Safety Information Summaries: Baycol (cerivastatin). Available at: http://www.fda.gov/medwatch/safety/2001/safety01.htm#bayco2. Accessed December 4, 2002.
24. Tomlinson B, Lan IW. Combination therapy with cerivastatin and gemfibrozil causing rhabdomyolysis: is the interaction predictable? Am J Med. 2001;110:669-670.
25. Kroon AA, Stalenhoef AF, Buikema H, et al. The effect of cholesterol reduction on the endothelial function and progression of atherosclerosis in WHHL rabbits. Atherosclerosis. 1993;103:221-230.
26. Stroes ES, Koomans HA, de-Bruin TW, et al. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet. 1995;346:467-471.
27. Vita JA, Yeung AC, Winniford M, et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation. 2000;102:846-851.
28. Kjekshus J, Pedersen TR. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1995;76:64C-68C.
29. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
30. The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol values. N Engl J Med. 1998;339:1349-1357.
31. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
32. Heeschen C, Hamm CW, Bruemmer J, et al. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis: CAPTURE Investigators: Chimeric c7E3 AntiPlatelet Therapy in Unstable angina Refractory to standard treatment trial. J Am Coll Cardiol. 2000;35:1535-1542.
33. Fichtlscherer S, Rosenberger G, Walter DH, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation. 2000;102:1000-1006.
34. Laufs U, Endres M, Custodis F. et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation. 2000;102:3104-3110.
35. Habib JB, Bossaller C, Wells S, et al. Preservation of endotheliumdependent vascular relaxation in cholesterol-fed rabbit by treatment with the calcium blocker PN 200110. Circ Res. 1986;58:305-309.
36. Verhaar MC, Honing ML, van-Dam T, et al. Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. Cardiovasc Res. 1999;42:752-760.
37. Lupo E, Locher R, Weisser B, et al. In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with alpha-tocopherol. Biochem Biophys Res Commun. 1994;203:1803-1808.
38. Pitt B, Byington RP, Furberg CD, et al, for the PREVENT Investigators. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 2000;102:1503-1510.
39. Lubsen J, Poole-Wilson PA, Pocock SJ, et al. Design and current status of ACTION: A coronary disease Trial Investigating Outcome with Nifedipine GITS (Gastro-Intestinal Therapeutic System). Eur Heart J. 1998;(suppl I):20-32.
40. Sech SM, Montoya JD, Bernier PA, et al. The so-called "placebo effect" in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring. Urology. 1998;51:242-250.
41. Nissen SE. Rationale for a postintervention continuum of care: insights from intravascular ultrasound. Am J Cardiol. 2000;86:12H-17H.